Generating your feed, please be patient ...

Latest news

Zootzle IntelligenceLilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 we... | Markets Insider | Zootzle